Research Article
Warfarin Use Is Associated with Increased Mortality at One Year in Patients with Idiopathic Pulmonary Fibrosis
Table 1
Baseline characteristics of the study population.
| | Variable | Total population | Warfarin group () | DOAC group () | value |
| | Age in years, mean (SD) | 73.78 (11.25) | | | 0.77 | | Male gender | 40 (54.8%) | 14 (50%) | 26 (57.8%) | 0.51 | | Comorbid conditions | | | | | | Diabetes | 27 (37%) | 14 (50%) | 13 (28.9%) | 0.07 | | Congestive heart failure | 31 (42.5%) | 13 (46.4%) | 18 (40%) | 0.59 | | Cerebrovascular disease | 11 (15.1%) | 5 (17.9%) | 6 (13.3%) | 0.60 | | Hypertension | 49 (67.1%) | 21 (75%) | 28 (62.2%) | 0.26 | | Coronary artery disease | 38 (52.1%) | 17 (60.7%) | 21 (46.7%) | 0.24 | | COPD | 16 (21.9%) | 5 (17.9%) | 11 (24.4%) | 0.51 | | History of malignancy | 19 (26%) | 5 (17.9%) | 14 (31.1%) | 0.21 | | Smoking history | 13 (7.8%) | 4 (14.3%) | 9 (20%) | 0.54 | | Antifibrotic agent use | 30 (41.1%) | 8 (28.6%) | 22 (48.9%) | 0.09 | | Nintedanib | | 3 (10.7%) | 9 (20%) | | | Pirfenidone | | 5 (17.8%) | 13 (28.9%) | | | Home oxygen use at initiation of anticoagulation | 24 (32.9%) | 5 (17.9%) | 19 (42.2%) | 0.03 | | DLCO at initiation of anticoagulation, mean (SD) | | | | 0.37 | | Concurrent use of antiplatelet therapy | 33 (45.2%) | 18 (64.3%) | 15 (33.3%) | 0.01 | | Indication for anticoagulation | | | | | | Atrial fibrillation | 45 (61.6%) | 16 (57.1%) | 29 (64.4%) | 0.39 | | CHA₂DS₂-VASc (median, IQR) | | 4 (1.5) | 4 (1.25) | | | Thromboembolism | 24 (32.9%) | 8 (28.6%) | 16 (35.6%) | 0.79 | | Inherited coagulopathy with thrombotic event | 4 (5.5%) | 3 (10.7%) | 1 (2.2%) | 0.12 |
|
|
